Liquidia Corporation (LT4)
XDUS 
Summary
LT4 Chart
People also search for
Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?
LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.
4 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, FLXS, ELMD & AGX
LQDA, FLXS, ELMD and AGX combine low beta, positive price momentum and strong fundamentals to help investors navigate market volatility.
LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
Liquidia has surged 129.7% so far in 2026 as Yutrepia gains traction, driving strong sales, profitability and higher earnings estimates.
Liquidia Corporation (LT4) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Liquidia Corporation ever had a stock split?
Liquidia Corporation Profile
| Biotechnology Industry | Healthcare Sector | Roger A. Jeffs CEO | XDUS Exchange | US53635D2027 ISIN |
| US Country | 216 Employees | - Last Dividend | - Last Split | 26 Jul 2018 IPO Date |
Overview
Liquidia Corporation is a pioneering biopharmaceutical entity based in Morrisville, North Carolina, established in 2004. With a vibrant commitment to addressing unmet patient needs across the United States, the company holds a prominent position in the development, manufacturing, and commercialization of innovative therapeutic products. Its endeavors are primarily centered around leveraging cutting-edge technologies to forge novel treatments for critical health conditions, with a significant emphasis on pulmonary disorders.
Products and Services
Liquidia Corporation's portfolio articulates its concentrated focus on respiratory diseases, particularly targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its product offerings and pipeline projects represent a blend of advanced research and strategic partnerships aiming to revolutionize patient care in these areas.
- YUTREPIA: An innovative inhaled dry powder formulation of treprostinil, YUTREPIA stands out as Liquidia's spearhead product candidate engineered for the treatment of PAH and PH-ILD. This front-runner product exemplifies the company's dedication to improving the quality of life for patients suffering from these severe pulmonary conditions, offering a new route of administration that potentially enhances efficacy, convenience, and tolerability.
- Remodulin: Another significant offering in its repertoire, Remodulin, signifies treprostinil in a transformative form, designed for continuous intravenous and subcutaneous infusion. This drug underscores the company’s efforts in providing enduring and effective treatment solutions tailored for the systemic management of PAH, affirming its commitment to advancing patient care in the domain of severe respiratory ailments.
- L606 (under license agreement with Pharmosa Biopharm Inc): The collaboration with Pharmosa Biopharm Inc for the development and commercialization of L606, an inhaled sustained-release formulation of treprostinil, demonstrates Liquidia’s strategy of embracing innovation through partnerships. Slated for the treatment of PAH and PH-ILD, L606 embodies the company's vision towards introducing next-generation therapeutics that promise to redefine treatment paradigms in pulmonary hypertension.
